Last reviewed · How we verify

NCT04776707

Reliability and Validity of the Turkish Version of Sensory Hypersensivity Scale

Status unknown Last updated 17 August 2021
What this trial tests

trial in Central Sensitisation in 100 participants. Status unknown.

Timeline
16 August 2021
Primary endpoint
1 March 2022
1 May 2022

Quick facts

Lead sponsorMarmara University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date16 August 2021
Primary completion1 March 2022
Estimated completion1 May 2022
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Marmara University

Who can join

Adults 18 to 75, any sex, with Central Sensitisation or Hypersensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Central sensitization (CS) is as increased response to normal or sub-threshold stimuli of central nervous system. Patient history and physical examination, quantitative sensory testing(QST), imaging methods, neuroinflammatory marker levels, electrodiagnostic studies and clinical scales can be used in the diagnosis of CS, but there is no standardized method yet. Among these methods, clinical scales are preferred because they are practical, inexpensive and do not require experience. The Sensory Hypersensitivity Scale was developed by Dixon et al. for investigate the personal hypersensitivity and CS. The aim of this study is to investigate the Turkish validity and reliability of the sensory hypersensitivity scale.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Central Sensitisation

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04776707.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing